“uniqure” Archives

in
Entry Author Date Location
Struggling UniQure Cuts Gene Therapies, Jobs, in Big Restructuring 11/15/16 Boston
Shire Steps Back in Hemophilia Gene Therapy Race, Scraps Baxalta Drug 08/03/16 Boston
More Gene Therapy Momentum as Startup Avrobio Grabs $25M From Atlas, SV 08/02/16 Boston
Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More 07/29/16 National
At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy 07/28/16 National
Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval 07/20/16 San Francisco
Spark Adds To Early But Promising Data For Hemophilia Gene Therapy 05/19/16 National
Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance 05/16/16 Boston
With BioMarin Data, Gene Therapy Finally Shows Impact on Hemophilia A 04/20/16 San Francisco
East Coast Bio Roundup: NY Startups, Editas, Bonney, C4 & (Much) More 01/08/16 Boston
UniQure’s Shares Rise on Early Gene Therapy Data For Hemophilia 01/07/16 National
Stewart Parker: Biotech Thoughts On Gene Therapy, GOP & Trout Streams 12/31/15 Seattle
Waving White Flag, Celladon Merges With Rare Disease Co. Eiger Bio 11/19/15 San Diego
Gene Therapy Startup Dimension Cuts Price But Bags $72M in IPO 10/21/15 Boston
Voyager Charts an IPO Course Amid Choppy Biotech Waters 10/11/15 Boston
Gene Therapy Startup Dimension Tx Takes Crossover Cash to IPO Queue 09/14/15 Boston
Shire Sends Hemophilia Gene Editing Prospects Back to Sangamo 09/02/15 San Francisco
East Coast Biotech Roundup: Editas, Checkmate, Ovid & More 08/14/15 Boston
In Biotech, Everyone’s Going Public. What’s Your Excuse? 07/22/15 National
Bluebird, Regulators Map Out Approval Plan For Gene Therapy 05/19/15 Boston
Hunting for an IPO? Voyager Gets $60M From “Crossover” Backers 04/13/15 Boston
East Coast Biotech Roundup: Cellectis, Bristol, What’s Hot & More 04/13/15 Boston
Gene Therapy’s Rebirth Continues With Bristol, UniQure Cardio Deal 04/06/15 New York
Stop the Bleeding: Can Gene Therapy Finally Cure Hemophilia? 03/23/15 National
Bluebird 4 For 4 As Gene Therapy Helps More Blood Disease Patients 12/08/14 Boston
With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray 11/18/14 Boston
Avalanche Bio Rolls Onto Nasdaq After Upsized, $102M IPO 07/31/14 San Francisco
Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study 06/14/14 Boston
Gene Therapy Lurches Ahead, Sees Thorny Future Questions on Price 01/27/14 National
Page 2 of 2 « previous page